Eli Lilly posted USD 28.3 billion in H1 2025 revenue, up 41% year-on-year, propelled by GLP-1 therapies tirzepatide (USD 14.7 billion) and dulaglutide (USD 2.2 billion). Obesity drug Zepbound (tirzepatide) surged 223% to USD 5.7 billion, while diabetes version Mounjaro grew 85% to USD 9 billion, narrowing the gap with Novo Nordisk's semaglutide (USD 16.7 billion). Lilly now leads the US GLP-1 market with 57% prescription share.

The company raised its full-year guidance to USD 60 to 62 billion, citing pipeline momentum including positive Phase III results for oral GLP-1 drug orforglipron. Oncology drug Verzenio (abemaciclib) rose 11% to USD 2.6 billion, while Lilly completed USD 4.8 billion in acquisitions (Verve Therapeutics, SiteOne Therapeutics, Scorpion Therapeutics) and USD 5 billion in partnerships. Upcoming milestones include ATTAIN-2 obesity trial data and potential heart failure with preserved ejection fraction (HFpEF) approval for Zepbound.

According to PharmCube's NextBiopharm® database, Mounjaro has experienced staggering growth since its 2022 launch. Click here to request a free trial for NextBiopharm®.